| abstract |
REFERS TO A COMPOUND OF FORMULA I OR A PHARMACEUTICALLY ACCEPTABLE SALT, WHERE: W IS -N (R * 3) -; R * 3 IS H, C1-C3 ALKYL; AND IT IS A COMPOUND OF FORMULA II, WHERE: RY1, RY2 AND RY3 ARE H, HALO, ALIPHATIC C1-C3, AMONG OTHERS; Z IS OPTIONALLY SUBSTITUTED ARYL, FUSED ARYL, HETEROARYL, AMONG OTHERS; THE PREFERRED COMPOUNDS ARE: (RAC) -REL-SULFAMATE OF ((1R, 2R, 3S, 4R) -2,3-DIHYDROXY-4- (2-PHENYLPYRAZOLE [1,5-A] PYRIMIDIN-7-ILAMINE) CYCLOPENTIL) METHYL; (RAC) -REL-SULFAMATE OF ((1R, 2R, 3S, 4R) -4- (2- (BIPHENYL-3-IL) PYRAZOLO [1,5-A] PYRIMIDIN-7-ILAMINO) -2,3- DIHYDROXYCLOPENTIL) METHYL; AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUND IS AN INHIBITOR OF THE ACTIVATING ENZYME OF UBIQUITIN (UAE). USEFUL IN THE TREATMENT OF CANCER. |